SIMILAR EFFICACY AND SAFETY OF BIOSIMILAR CANDIDATE BI 695501 AND ADALIMUMAB ORIGINATOR REFERENCE PRODUCT IN PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS: 24 WEEK RESULTS FROM A PHASE III CLINICAL STUDY (VOLTAIRE®-RA)

被引：2
|
作者：
Cohen, S. [1 ]
Alonso-Ruiz, A. [2 ]
Klimiuk, P. A. [3 ,4 ]
Lee, E. [5 ]
Peter, N. [6 ]
Sonderegger, I. [6 ]
Assudani, D. [6 ]
机构：
[1] Metroplex Clin Res Ctr, Dallas, TX USA
[2] Hosp Cruces, Baracaldo, Spain
[3] Med Univ Bialystok, Bialystok, Poland
[4] Gabinet InternistycznoReumatol, Bialystok, Poland
[5] Inland Rheumatol, Upland, CA USA
[6] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2017年 / 76卷
关键词：
D O I：
10.1136/annrheumdis-2017-eular.3405
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
FRI0189
引用
收藏
页码：553 / 553
页数：1
相关论文
共 50 条
  • [21] A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis
    Roy M. Fleischmann
    Rieke Alten
    Margarita Pileckyte
    Kasia Lobello
    Steven Y. Hua
    Carol Cronenberger
    Daniel Alvarez
    Amy E. Bock
    K. Lea Sewell
    Arthritis Research & Therapy, 20
  • [22] Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study
    Jonathan Kay
    Janusz Jaworski
    Rafal Wojciechowski
    Piotr Wiland
    Anna Dudek
    Marek Krogulec
    Slawomir Jeka
    Agnieszka Zielinska
    Jakub Trefler
    Katarzyna Bartnicka-Maslowska
    Magdalena Krajewska-Wlodarczyk
    Piotr A. Klimiuk
    Sang Joon Lee
    Yun Ju Bae
    Go Eun Yang
    Jae Kyoung Yoo
    Daniel E. Furst
    Edward Keystone
    Arthritis Research & Therapy, 23
  • [23] Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study
    Kay, Jonathan
    Jaworski, Janusz
    Wojciechowski, Rafal
    Wiland, Piotr
    Dudek, Anna
    Krogulec, Marek
    Jeka, Slawomir
    Zielinska, Agnieszka
    Trefler, Jakub
    Bartnicka-Maslowska, Katarzyna
    Krajewska-Wlodarczyk, Magdalena
    Klimiuk, Piotr A.
    Lee, Sang Joon
    Bae, Yun Ju
    Yang, Go Eun
    Yoo, Jae Kyoung
    Furst, Daniel E.
    Keystone, Edward
    ARTHRITIS RESEARCH & THERAPY, 2021, 23 (01)
  • [24] Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis Fifty-Two-Week Phase III Randomized Study Results
    Weinblatt, Michael E.
    Baranauskaite, Asta
    Dokoupilova, Eva
    Zielinska, Agnieszka
    Jaworski, Janusz
    Racewicz, Artur
    Pileckyte, Margarita
    Jedrychowicz-Rosiak, Krystyna
    Baek, Inyoung
    Ghil, Jeehoon
    ARTHRITIS & RHEUMATOLOGY, 2018, 70 (06) : 832 - 840
  • [25] Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study
    Cohen, Stanley
    Genovese, Mark C.
    Choy, Ernest
    Perez-Ruiz, Fernando
    Matsumoto, Alan
    Pavelka, Karel
    Pablos, Jose L.
    Rizzo, Warren
    Hrycaj, Pawel
    Zhang, Nan
    Shergy, William
    Kaur, Primal
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (10) : 1679 - 1687
  • [26] EFFICACY AND SAFETY OF BARICITINIB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO CSDMARDS: SUMMARY RESULTS FROM THE 24-WEEK PHASE III RA-BUILD STUDY
    Emery, Paul
    Krogulec, Marek
    Blanco Alonso, Ricardo
    Rossini, Maurizio
    Raeman, Frank
    Walker, David
    Ghizdavescu, Andrei Petru
    Irto, Ildiko
    Luz Rentero, Maria
    Casillas, Marta
    de la Torre, Inmaculada
    Dougados, Maxime
    RHEUMATOLOGY, 2016, 55 : 60 - 60
  • [27] Further clinical outcomes in patients with moderate-to-severe chronic plaque psoriasis receiving adalimumab reference product continuously or switching between BI 695501 and adalimumab RP in the phase III, randomized, interchangeability VOLTAIRE-X trial
    Menter, Alan
    McCabe, Dorothy
    Lang, Benjamin
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB61 - AB61
  • [28] BARICITINIB IN THE TREATMENT OF PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS IN CHINA: 24-WEEK RESULTS OF POSTMARKETING SAFETY STUDY
    Wu, C. Y.
    Wang, Q.
    Shi, J.
    Zhang, X.
    Du, R.
    Gu, J.
    Liu, Q. H.
    Yu, J.
    Xu, J. W.
    Zhang, Y. J.
    Zhu, H.
    Li, M.
    Zeng, X.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1418 - 1418
  • [29] Successful administration of BI 695501, an adalimumab biosimilar, using an autoinjector (AI): results from a Phase II open-label clinical study (VOLTAIRE®-RL)
    Cohen, Stanley
    Klimiuk, Piotr A.
    Krahnke, Tillmann
    Assudani, Deepak
    EXPERT OPINION ON DRUG DELIVERY, 2018, 15 (06) : 545 - 548
  • [30] Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study
    Matucci-Cerinic, Marco
    Allanore, Yannick
    Kavanaugh, Arthur
    Buch, Maya H.
    Schulze-Koops, Hendrik
    Kucharz, Eugeniusz J.
    Woehling, Heike
    Babic, Goran
    Poetzl, Johann
    Davis, Adanna
    Schwebig, Arnd
    RMD OPEN, 2018, 4 (02):
12345